Alivus Life Sciences Reports 6.9% YoY Revenue Growth for FY26, EBITDA Margins Hit 33.6%

Alivus Life Sciences Reports 6.9% YoY Revenue Growth for FY26, EBITDA Margins Hit 33.6%​

Alivus Life Sciences Limited, a major developer and manufacturer of high-value, non-commoditized Active Pharmaceutical Ingredients (APIs), announced its financial results for the quarter and full year ended March 31, 2026. The company reported robust financial performance, noting a 6.9% year-on-year (YoY) growth in revenue from operations for FY26.

For the full fiscal year 2026, Alivus posted revenue from operations of Rs. 25,518 Mn. The quarterly results showed revenue from operations for Q4FY26 stood at Rs. 6,891 Mn, reflecting a 6.1% YoY growth.

The company's profitability metrics also showed significant improvement. For FY26, EBITDA was Rs. 8,577 Mn, marking a 19.6% YoY increase. EBITDA margins for the year reached 33.6%, an improvement of 360 basis points (bps) YoY. In Q4FY26, EBITDA was Rs. 2,373 Mn, with margins of 34.4%, up 230 bps YoY.


For Q4FY26, the company reported a Profit After Tax (PAT) of Rs. 1,627 Mn, which represents a 14.7% YoY growth. PAT margins for the quarter were 23.6%, up 180 bps YoY.

The company also reported strong cash generation, with free cash flow reaching Rs. 2,590 Mn during FY26. As of March 31, 2026, Cash and Cash Equivalents (including short term investments) stood at Rs. 7,824 Mn.

Operational Highlights and Strategic Growth​

Dr. Yasir Rawjee, MD & CEO of Alivus Life Sciences Limited, noted that the FY26 results reflected a clear operational improvement. He highlighted that the revenue growth was supported by a 13% increase in the non-GPL business segment, which fueled the 19.6% EBITDA growth. The CDMO business specifically delivered a turnaround, achieving 18% YoY growth. He also pointed to healthy momentum across key global regions, including India, Europe, ROW, Japan, and LATAM.

Tushar Mistry, CFO, stated that the strong momentum continued into Q4FY26, with 6.1% YoY revenue growth. He emphasized that the performance was broad-based across nearly all regions. He reaffirmed that the full year's EBITDA margins of 33.6% exceeded the guided range of 30-32%, driven by a favorable product mix and disciplined expense management.

R&D and Capacity Expansion​

In terms of business development, the company noted that its total cumulative DMF/CEP filings across major markets reached 611 as of March 31, 2026. The HP API portfolio currently includes 28 APIs in the active grid, of which 12 are validated, seven are in advanced development, and nine are progressing through laboratory development stages.

On the expansion front, Alivus Life Sciences continues its capital expenditure plans. Construction work is in progress at the Solapur facility for Phase 1 and 1.1, targeting a capacity of 465 KL. Furthermore, the company has acquired 10,000 square meters of land in Taloja (Navi Mumbai) to establish a state-of-the-art R&D centre. This new facility will focus on advancing complex chemistry and oncology research, specializing in areas such as flow chemistry, complex products, particle engineering, and green chemistry. Construction work for this new R&D center has already commenced.

Alivus Life Sciences Limited, which supplies 176 molecules, operates four manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh, boasting a total installed capacity of 1424 KL. These facilities are regularly audited by global regulators, including USFDA, PMDA (Japan), and EDQM (Europe).

ALIVUS Stock Price Movement​

Today, Alivus Life Sciences Limited shares shed 1.37% of value, settling at ₹1064.1. The stock saw consistent activity, with 81,151 shares transacted during the trading session today.